Difference between revisions of "Section 3: IFN-lambda as an antiviral drug (from DOI: 10.1084/jem.20200653) (Q11180)"
Jump to navigation
Jump to search
(Created claim: IMRaD(C) Section (P124): Introduction (Q7978), #quickstatements; #temporary_batch_1593027137586) |
(Created claim: Section or subsection level in publication (P148): Main section in publication (Q7807), #quickstatements; #temporary_batch_1593027137586) |
||
| Property / Section or subsection level in publication | |||
| + | |||
| Property / Section or subsection level in publication: Main section in publication / rank | |||
| + | Normal rank | ||
Latest revision as of 19:32, 24 June 2020
Publication: "COVID-19 and emerging viral infections: The case for interferon lambda"published as J. Exp. Med.; 2020 05 04 ; 217 (5); DOI: 10.1084/jem.20200653
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 3: IFN-lambda as an antiviral drug (from DOI: 10.1084/jem.20200653)
|
Publication: "COVID-19 and emerging viral infections: The case for interferon lambda"published as J. Exp. Med.; 2020 05 04 ; 217 (5); DOI: 10.1084/jem.20200653
|
Statements
0 references
